After initial rush, semaglutide therapy market saddled with 100cr excess stock

NEW DELHI: The much-hyped weight-loss and semaglutide therapy market has hit an early speed bump. Sluggish sales of semaglutide therapies in May have raised fears of inventory-led losses, with industry estimates pegging the value of excess stock in the trade channel at around Rs 100 crore, sources told TOI.

Raccontata datimesofindia.indiatimes.com